Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.
Case: A 57-Year-Old Man with ALK+ NSCLC
Initial Presentation
Clinical Workup
Treatment